361 related articles for article (PubMed ID: 29564181)
1. Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response.
Rosenberg A; Mahalingam D
J Gastrointest Oncol; 2018 Feb; 9(1):143-159. PubMed ID: 29564181
[TBL] [Abstract][Full Text] [Related]
2. Advances in Immunotherapeutics in Pancreatic Ductal Adenocarcinoma.
Chouari T; La Costa FS; Merali N; Jessel MD; Sivakumar S; Annels N; Frampton AE
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686543
[TBL] [Abstract][Full Text] [Related]
3. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
[TBL] [Abstract][Full Text] [Related]
4. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
5. Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance.
Heumann T; Azad N
Cancer Metastasis Rev; 2021 Sep; 40(3):837-862. PubMed ID: 34591243
[TBL] [Abstract][Full Text] [Related]
6. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
Nelson A; Gebremeskel S; Lichty BD; Johnston B
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
[TBL] [Abstract][Full Text] [Related]
7. Advances in Pancreatic Ductal Adenocarcinoma Treatment.
Anderson EM; Thomassian S; Gong J; Hendifar A; Osipov A
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771675
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for pancreatic cancer: A 2020 update.
Schizas D; Charalampakis N; Kole C; Economopoulou P; Koustas E; Gkotsis E; Ziogas D; Psyrri A; Karamouzis MV
Cancer Treat Rev; 2020 Jun; 86():102016. PubMed ID: 32247999
[TBL] [Abstract][Full Text] [Related]
9. Opportunities and challenges of combining adoptive cellular therapy with oncolytic virotherapy.
Mamola JA; Chen CY; Currier MA; Cassady K; Lee DA; Cripe TP
Mol Ther Oncolytics; 2023 Jun; 29():118-124. PubMed ID: 37250971
[TBL] [Abstract][Full Text] [Related]
10. Viro-immune therapy: A new strategy for treatment of pancreatic cancer.
Ibrahim AM; Wang YH
World J Gastroenterol; 2016 Jan; 22(2):748-63. PubMed ID: 26811622
[TBL] [Abstract][Full Text] [Related]
11. Advances in immunotherapy for pancreatic ductal adenocarcinoma.
Miyazawa M; Katsuda M; Kawai M; Hirono S; Okada KI; Kitahata Y; Yamaue H
J Hepatobiliary Pancreat Sci; 2021 May; 28(5):419-430. PubMed ID: 33742512
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic Cancer and Immunotherapy: A Clinical Overview.
Timmer FEF; Geboers B; Nieuwenhuizen S; Dijkstra M; Schouten EAC; Puijk RS; de Vries JJJ; van den Tol MP; Bruynzeel AME; Streppel MM; Wilmink JW; van der Vliet HJ; Meijerink MR; Scheffer HJ; de Gruijl TD
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439292
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic virotherapy for pancreatic ductal adenocarcinoma: A glimmer of hope after years of disappointment?
Tassone E; Muscolini M; van Montfoort N; Hiscott J
Cytokine Growth Factor Rev; 2020 Dec; 56():141-148. PubMed ID: 32859494
[TBL] [Abstract][Full Text] [Related]
14. Impact of gut microbiome in the development and treatment of pancreatic cancer: Newer insights.
Bangolo AI; Trivedi C; Jani I; Pender S; Khalid H; Alqinai B; Intisar A; Randhawa K; Moore J; De Deugd N; Faisal S; Suresh SB; Gopani P; Nagesh VK; Proverbs-Singh T; Weissman S
World J Gastroenterol; 2023 Jul; 29(25):3984-3998. PubMed ID: 37476590
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic ductal adenocarcinoma: Emerging therapeutic strategies.
Osei-Bordom DC; Serifis N; Brown ZJ; Hewitt DB; Lawal G; Sachdeva G; Cloonan DJ; Pawlik TM
Surg Oncol; 2022 Aug; 43():101803. PubMed ID: 35830772
[TBL] [Abstract][Full Text] [Related]
16. Machine learning-based integration develops a metabolism-derived consensus model for improving immunotherapy in pancreatic cancer.
Guo Y; Wang R; Shi J; Yang C; Ma P; Min J; Zhao T; Hua L; Song Y; Li J; Su H
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37739440
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment.
Looi CK; Chung FF; Leong CO; Wong SF; Rosli R; Mai CW
J Exp Clin Cancer Res; 2019 Apr; 38(1):162. PubMed ID: 30987642
[TBL] [Abstract][Full Text] [Related]
18. Regulation of autophagy fires up the cold tumor microenvironment to improve cancer immunotherapy.
Jin Z; Sun X; Wang Y; Zhou C; Yang H; Zhou S
Front Immunol; 2022; 13():1018903. PubMed ID: 36300110
[TBL] [Abstract][Full Text] [Related]
19. New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy.
Lowery MA; O'Reilly EM
BioDrugs; 2011 Aug; 25(4):207-16. PubMed ID: 21815696
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic Immunotherapy: Can't Start a Fire Without a Spark.
Muscolini M; Tassone E; Hiscott J
Cytokine Growth Factor Rev; 2020 Dec; 56():94-101. PubMed ID: 32826166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]